Figure 1From: A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension Subject disposition. Flow chart of subjects detailing number of randomized subjects in each group, number of subjects withdrawing from the study, and the PP population by group.Back to article page